Literature DB >> 20117293

Irradiation-induced regulation of plasminogen activator inhibitor type-1 and vascular endothelial growth factor in six human squamous cell carcinoma lines of the head and neck.

Tuuli Artman1, Daniela Schilling, Julia Gnann, Michael Molls, Gabriele Multhoff, Christine Bayer.   

Abstract

PURPOSE: It has been shown that plasminogen activator inhibitor type-1 (PAI-1) and vascular endothelial growth factor (VEGF) are involved in neo-angiogenesis. The aim of this study was to investigate the irradiation-induced regulation of PAI-1 and VEGF in squamous cell carcinomas of the head and neck (SCCHN) cell lines of varying radiation sensitivity. METHODS AND MATERIALS: Six cell lines derived from SCCHN were investigated in vitro. The colorimetric AlamarBlue assay was used to detect metabolic activity of cell lines during irradiation as a surrogate marker for radiation sensitivity. PAI-1 and VEGF secretion levels were measured by enzyme-linked immunosorbent assay 24, 48, and 72 h after irradiation with 0, 2, 6, and 10 Gy. The direct radioprotective effect of exogenous PAI-1 was measured using the clonogenic assay. For regulation studies, transforming growth factor-beta1 (TGF-beta1), hypoxia-inducible factor-1alpha (HIF-1alpha), hypoxia-inducible factor-2alpha (HIF-2alpha), or both HIF-1alpha and HIF-2alpha were downregulated using siRNA.
RESULTS: Although baseline levels varied greatly, irradiation led to a comparable dose-dependent increase in PAI-1 and VEGF secretion in all six cell lines. Addition of exogenous stable PAI-1 to the low PAI-1-expressing cell lines, XF354 and FaDu, did not lead to a radioprotective effect. Downregulation of TGF-beta1 significantly decreased VEGF secretion in radiation-sensitive XF354 cells, and downregulation of HIF-1alpha and HIF-2alpha reduced PAI-1 and VEGF secretion in radiation-resistant SAS cells.
CONCLUSIONS: Irradiation dose-dependently increased PAI-1 and VEGF secretion in all SCCHN cell lines tested regardless of their basal levels and radiation sensitivity. In addition, TGF-beta1 and HIF-1alpha could be partly responsible for VEGF and PAI-1 upregulation after irradiation. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20117293     DOI: 10.1016/j.ijrobp.2009.08.035

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Prediction of locoregional control in head and neck squamous cell carcinoma with serial CT perfusion during radiotherapy.

Authors:  M T Truong; N Saito; A Ozonoff; J Wang; R Lee; M M Qureshi; S Jalisi; O Sakai
Journal:  AJNR Am J Neuroradiol       Date:  2011-07-14       Impact factor: 3.825

2.  Radiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1α.

Authors:  Daniela Schilling; Christine Bayer; Wei Li; Michael Molls; Peter Vaupel; Gabriele Multhoff
Journal:  PLoS One       Date:  2012-02-07       Impact factor: 3.240

3.  PAI-1-dependent endothelial cell death determines severity of radiation-induced intestinal injury.

Authors:  Rym Abderrahmani; Agnes François; Valerie Buard; Georges Tarlet; Karl Blirando; Mohammad Hneino; Aurelie Vaurijoux; Marc Benderitter; Jean-Christophe Sabourin; Fabien Milliat
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

4.  Genetic polymorphisms of PAI-1 and PAR-1 are associated with acute normal tissue toxicity in Chinese rectal cancer patients treated with pelvic radiotherapy.

Authors:  Hui Zhang; Mengyun Wang; Tingyan Shi; Lijun Shen; Ji Zhu; Menghong Sun; Yun Deng; Liping Liang; Guichao Li; Yongxin Wu; Ming Fan; Qingyi Wei; Zhen Zhang
Journal:  Onco Targets Ther       Date:  2015-08-27       Impact factor: 4.147

Review 5.  uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.

Authors:  Miguel Angel Pavón; Irene Arroyo-Solera; Maria Virtudes Céspedes; Isolda Casanova; Xavier León; Ramón Mangues
Journal:  Oncotarget       Date:  2016-08-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.